04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:49 , Mar 28, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML) In vitro and mouse studies suggest combining Gleevec imatinib with inhibition of c-fos and DUSP1 could help treat CML. In patient peripheral blood monocytes (PBMCs), levels of c-fos and DUSP1...
07:00 , Nov 4, 2010 |  BC Innovations  |  Targets & Mechanisms

Depression paths of least resistance

A pair of reports from U.S. and European researchers point to new targets in depression that could offer treatment alternatives to patients who are resistant or unresponsive to marketed antidepressants. 1,2 One of the new...
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Dual specificity phosphatase 1 (DUSP1; MPK1) Patient tissue samples and mouse studies suggest that inhibiting MPK1 could help treat depression. In a whole-genome analysis...